Pharma News

 

Pfizer
Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The first boy received an infusion of the mini-dystrophin gene on March 22nd, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics [...]
Mon, Apr 23, 2018
Source Pharmanews
Older adults who take a novel antioxidant that specifically targets cellular powerhouses, or mitochondria, see age-related vascular changes reverse by the equivalent of 15 to 20 years within six weeks, according to new University of Colorado Boulder research. The study, published this week in the American Heart Association journal Hypertension, [...]
Fri, Apr 20, 2018
Source Pharmanews
Novo Nordisk
The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk today announced a partnership to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. [...]
Thu, Apr 19, 2018
Source Pharmanews
FDA
The U.S. Food and Drug Administration has approved Crysvita (burosumab-twza), the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets. XLH causes low levels of phosphorus in the blood. It leads to impaired bone growth and [...]
Thu, Apr 19, 2018
Source Pharmanews

 

(by Worldpharmanews)

Contact us
Medial D&P Ltd.
Gewerbestrasse 18
4123 Allschwil
Switzerland
Phone: +41 61 487 96 22
Fax. +41 61 487 96 20
medial@medialpharma.com